Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15313535rdf:typepubmed:Citationlld:pubmed
pubmed-article:15313535lifeskim:mentionsumls-concept:C0314752lld:lifeskim
pubmed-article:15313535lifeskim:mentionsumls-concept:C0684224lld:lifeskim
pubmed-article:15313535lifeskim:mentionsumls-concept:C2745955lld:lifeskim
pubmed-article:15313535lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:15313535lifeskim:mentionsumls-concept:C1136254lld:lifeskim
pubmed-article:15313535lifeskim:mentionsumls-concept:C1521828lld:lifeskim
pubmed-article:15313535lifeskim:mentionsumls-concept:C1515095lld:lifeskim
pubmed-article:15313535lifeskim:mentionsumls-concept:C0022341lld:lifeskim
pubmed-article:15313535pubmed:issue4lld:pubmed
pubmed-article:15313535pubmed:dateCreated2004-8-17lld:pubmed
pubmed-article:15313535pubmed:abstractTextMetallo-beta-lactamases (M beta L) were initially characterized in Japan, usually of the IMP-type, and found in Pseudomonas aeruginosa (PSA), Acinetobacter spp. (ACB), or Serratia marcescens (SM). The number of M beta L types has increased worldwide, but geographic dissemination within Japan has appeared limited. This study compares baseline levels of M beta L resistance from two 22-center studies (1996-1997) to the longitudinal sample (3 sites) of Japanese isolates from the SENTRY Antimicrobial Surveillance Program (1998-2002). All minimal inhibitory concentration results were determined by reference methods. A total of 26.8% PSA, 3.4% ACB, and 3.1% Enterobacteriaceae (enterobacters and SM) with resistance to monitored carbapenems (CARB) (minimal inhibitory concentration, > or =8 microg/mL) were screened for M beta L production by disk approximation tests (EDTA and 2-MPA inhibitors), CARB hydrolysis by enzyme extracts, and selected PCR primers for known M beta L types. All M beta L-positive strains (10) were sequenced to determine enzyme identification. Clonality in each center was determined by automated ribotyping and PFGE. The CARB susceptibility rates in PSA decreased (80.7% to 62.0%) over the monitored interval (1998-2002), but varied by medical center location. Among CARB-resistant isolates, 10.8% were attributed to M beta L strains (1.1% of all PSA tested). M beta L identification showed the following: five PSA (three IMP-1, two IMP-2), four SM (one IMP-1, two IMP-1 + OXA-1, and one IMP-11). Also a single ACB had an IMP-1. Eight of 10 M beta L isolations occurred between 2000 and 2002; four occurred in 2002. BRL42715, an AMP-C inhibitor, confirmed AMP-C-mediated resistance in 87.3% of PSA, and outer membrane protein changes were also discovered by membrane studies. Prior results (22 sites, 1997-1998) showed CARB resistance at 22.4-25.6% and 0.5-0.9% M beta Ls (IMP-1) overall; it was slightly elevated in this SENTRY Program sample. In conclusion, M beta L-producing strains from several species persist in Japan, but represent a distinct minority of all CARB-resistant strains (1998-2002). Although M beta L rates appear generally stable in Japan, continued surveillance for these mechanisms seems to be a prudent practice, because of the mobility of the genetic determinants and the emergence of novel enzyme types, especially among the Enterobacteriaceae.lld:pubmed
pubmed-article:15313535pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15313535pubmed:languageenglld:pubmed
pubmed-article:15313535pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15313535pubmed:citationSubsetIMlld:pubmed
pubmed-article:15313535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15313535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15313535pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15313535pubmed:statusMEDLINElld:pubmed
pubmed-article:15313535pubmed:monthAuglld:pubmed
pubmed-article:15313535pubmed:issn0732-8893lld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:KohnoShigeruSlld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:InoueMatsuhis...lld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:OnoYasuoYlld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:JonesRonald...lld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:BellJan MJMlld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:TurnidgeJohn...lld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:MiyazawaYukih...lld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:HirakataYoich...lld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:TolemanMark...lld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:DeshpandeLali...lld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:KawakamaSayok...lld:pubmed
pubmed-article:15313535pubmed:authorpubmed-author:HirataYasuyos...lld:pubmed
pubmed-article:15313535pubmed:issnTypePrintlld:pubmed
pubmed-article:15313535pubmed:volume49lld:pubmed
pubmed-article:15313535pubmed:ownerNLMlld:pubmed
pubmed-article:15313535pubmed:authorsCompleteYlld:pubmed
pubmed-article:15313535pubmed:pagination289-94lld:pubmed
pubmed-article:15313535pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15313535pubmed:meshHeadingpubmed-meshheading:15313535...lld:pubmed
pubmed-article:15313535pubmed:meshHeadingpubmed-meshheading:15313535...lld:pubmed
pubmed-article:15313535pubmed:meshHeadingpubmed-meshheading:15313535...lld:pubmed
pubmed-article:15313535pubmed:meshHeadingpubmed-meshheading:15313535...lld:pubmed
pubmed-article:15313535pubmed:meshHeadingpubmed-meshheading:15313535...lld:pubmed
pubmed-article:15313535pubmed:meshHeadingpubmed-meshheading:15313535...lld:pubmed
pubmed-article:15313535pubmed:meshHeadingpubmed-meshheading:15313535...lld:pubmed
pubmed-article:15313535pubmed:meshHeadingpubmed-meshheading:15313535...lld:pubmed
pubmed-article:15313535pubmed:meshHeadingpubmed-meshheading:15313535...lld:pubmed
pubmed-article:15313535pubmed:meshHeadingpubmed-meshheading:15313535...lld:pubmed
pubmed-article:15313535pubmed:meshHeadingpubmed-meshheading:15313535...lld:pubmed
pubmed-article:15313535pubmed:year2004lld:pubmed
pubmed-article:15313535pubmed:articleTitleEvaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002).lld:pubmed
pubmed-article:15313535pubmed:affiliationThe JONES Group/JMI Laboratories, North Liberty, IA, USA. ronald-jones@jmilabs.comlld:pubmed
pubmed-article:15313535pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15313535pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15313535lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15313535lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15313535lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15313535lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15313535lld:pubmed